Medicina de Emergências
Diretriz de prática clínica da AGA sobre o tratamento de distúrbios de coagulação em pacientes com cirrose.
1 Out, 2021 | 19:20hVer também: AGA Technical Review on Coagulation in Cirrhosis – Gastroenterology
Revisão | Implementação de um algoritmo de exclusão precoce para o infarto agudo do miocárdio na prática clínica.
1 Out, 2021 | 19:11hImplementing an early rule-out pathway for acute myocardial infarction in clinical practice – Heart
Revisão | Condições cutâneas ameaçadoras à vida na terapia intensiva.
1 Out, 2021 | 18:25hLife-threatening skin conditions presenting to critical care – BJA Education
Podcast | Neutropenia febril.
1 Out, 2021 | 18:20h#288 LIVE! Neutropenic Fever featuring Dr. Susan Seo – The Curbsiders
Diretriz OMS atualizada | Terapias e COVID-19.
27 Set, 2021 | 13:31hTherapeutics and COVID-19: living guideline – World Health Organization
Ver também:
WHO recommends antibody treatment for COVID patients at high risk of hospital admission.
Comentário: WHO adds new recommendation for COVID-19 monoclonal antibody combo – CIDRAP
Avaliação de custo-efetividade da transfusão de plasma em ambiente pré-hospitalar em pacientes de trauma instáveis: uma análise secundária do estudo PAMPer.
27 Set, 2021 | 13:16hEvaluating the Cost-effectiveness of Prehospital Plasma Transfusion in Unstable Trauma Patients: A Secondary Analysis of the PAMPer Trial – JAMA Surgery (gratuito por tempo limitado)
Comentários:
CHEERS to You on a Well-done Cost-effectiveness Analysis of Prehospital Plasma for Helicopter Resuscitation of Patients With Traumatic Shock – JAMA Surgery (gratuito por tempo limitado)
Prehospital Plasma: A Cheap, Effective Way to Save Trauma Patients’ Lives? – BreakingMed
Comentário no Twitter
A cost-effectiveness analysis of the pragmatic, randomized, multicenter PAMPer trial reveals thawed plasma administration for trauma patients in hemorrhagic shock during air medical transport is life-saving and cost-effective https://t.co/WDCoJctZox
— JAMA Surgery (@JAMASurgery) September 24, 2021
[Preprint] Estudo randomizado PRINCIPLE | Colchicina não melhora o tempo de recuperação de pacientes com Covid-19 sob alto risco de complicações.
27 Set, 2021 | 12:52hConteúdo relacionado:
Comentário no Twitter
While COLCORONA trial found limited evidence that colchicine may reduce COVID-19 related hospitalisation/death
🆕💥💥@TrialPrinciple preprint
Colchicine did NOT improve time to recovery in people at higher risk of complications w COVID-19 in the communityhttps://t.co/2sUoeD7sGV pic.twitter.com/fi2THbxewW— Antibiotic Stewa®️xd 🆔🇵🇸 Bassam Ghanem (@ABsteward) September 23, 2021
OMS recomenda tratamento com anticorpos para pacientes com COVID-19 sob alto risco de internação hospitalar.
27 Set, 2021 | 12:50hArtigo original e infográfico: A living WHO guideline on drugs for covid-19 – The BMJ
Revisão sistemática | Características clínicas da síndrome inflamatória multissistêmica em adultos.
27 Set, 2021 | 12:08h
Comentário no Twitter
Multisystem inflammatory syndrome has been reported in adults worldwide but may be hard to distinguish from acute biphasic #COVID19 and postacute sequelae of COVID-19. More research is needed to understand this emerging clinical entity. https://t.co/OnerzsZKVB
— JAMA Network Open (@JAMANetworkOpen) September 22, 2021